Effects of enzyme induction on metabolism of prednisolone. Clinical and laboratory study.
The addition of phenobarbitone in therapeutic dosage to the drug regimen of prednisolone-treated subjects with rheumatoid arthritis produced measurable deterioration in the clinical status of the patients associated with a more rapid clearance of prednisolone from plasma. It is considered that phenobarbitone induced the hepatic metabolism of prednisolone, effectively reducing the steady state plasma level and resulting in clinical relapse. A slight but significant improvement in the adrenocortical response to tetracosactrin (Synacthen) was noted after phenobarbitone therapy.
D015062:11-Hydroxycorticosteroids / Q000097:blood; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003366:Cosyntropin / Q000494:pharmacology; D004347:Drug Interactions; D004790:Enzyme Induction; D006207:Half-Life; D006801:Humans; D008862:Microsomes, Liver / Q000201:enzymology*; D008875:Middle Aged; D010634:Phenobarbital / Q000494:pharmacology*; D011239:Prednisolone / Q000378:metabolism* / Q000627:therapeutic use
D015062:11-Hydroxycorticosteroids; D003366:Cosyntropin; D011239:Prednisolone; D010634:Phenobarbital